Further, Her2 + and triple-negative patients had a higher expression of FBLN2 compared to LumA and LumB at lesions of invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), and control regions (Supplementary Fig. 7). This evidence concerns the gene FBLN2 and invasive ductal breast carcinoma.